Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib

Clinical trial NCT07428018 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07428018
Sponsor: Mario Negri Institute for Pharmacological Research
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer HER2 + Breast Cancer HR Positive Neoadjuvant Therapy

Start date: 2026-04-30
Primary completion: 2029-04-30
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.